Trial · NCT03677141
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group A1: Phase Ib Mosunetuzumab + CHOP | 3 | |
| Overall Study | STARTED | Group A2: Phase Ib Mosunetuzumab + CHOP | 4 | |
| Overall Study | STARTED | Group B: Phase Ib Mosunetuzumab + CHP-Pola | 8 | |
| Overall Study | STARTED | Group C: Phase II Mosunetuzumab + CHOP | 40 | |
| Overall Study | STARTED | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 40 | |
| Overall Study | STARTED | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 22 | |
| Overall Study | COMPLETED | Group A1: Phase Ib Mosunetuzumab + CHOP | 1 | |
| Overall Study | COMPLETED | Group A2: Phase Ib Mosunetuzumab + CHOP | 3 | |
| Overall Study | COMPLETED | Group B: Phase Ib Mosunetuzumab + CHP-Pola | 1 | |
| Overall Study | COMPLETED | Group C: Phase II Mosunetuzumab + CHOP | 28 | |
| Overall Study | COMPLETED | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 31 | |
| Overall Study | COMPLETED | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 19 | |
| Overall Study | NOT COMPLETED | Group A1: Phase Ib Mosunetuzumab + CHOP | 2 | |
| Overall Study | NOT COMPLETED | Group A2: Phase Ib Mosunetuzumab + CHOP | 1 | |
| Overall Study | NOT COMPLETED | Group B: Phase Ib Mosunetuzumab + CHP-Pola | 7 | |
| Overall Study | NOT COMPLETED | Group C: Phase II Mosunetuzumab + CHOP | 12 | |
| Overall Study | NOT COMPLETED | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 9 | |
| Overall Study | NOT COMPLETED | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03677141/flow